Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

Item

http://www.wikidata.org/entity/Q33405150

Q33405150

about

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy Targeted Therapies in Adult B-Cell Malignancies Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia.Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation Novel agents for the treatment of childhood acute leukemia.A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Linked-in: design and efficacy of antibody drug conjugates in oncology Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.Advances in the treatment of hematologic malignancies using immunoconjugates Antibody therapy for pediatric leukemia.Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies.How we manage follicular lymphoma.Monoclonal antibodies as therapeutics in human malignancies.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.Chemotherapy-free treatment in patients with follicular lymphoma.Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.Emerging antibody-drug conjugates for treating lymphoid malignancies.Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.Breakthrough therapies in B-cell non-Hodgkin lymphoma.Adapting conventional cancer treatment for immunotherapy.New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.Targeting indolent non-Hodgkin lymphoma.Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.Rituximab for the treatment of follicular lymphoma.

P2860

Q26782270-9FD58A86-24F0-4BE0-8B8B-1B3F917A5E64 Q26783195-66856932-5D87-41E9-8EB0-4A86B0123173 Q26993238-B796D33A-2EBE-4C3B-84A7-0C630814F536 Q27304386-54415B90-DBC4-40F3-A6A1-D0C73C3D1915 Q28088365-178550DB-F2D4-4AF8-87B5-A34E4EAC0E14 Q33420631-6A159CD7-4347-4200-B162-8C119F6EFBC4 Q33431680-38CF9CE9-FBAA-45C0-9E0F-BA77575E7A89 Q33925386-8EDC55B6-2E48-4B2B-A142-1FD0E24E830A Q33954595-62ED0833-F385-4B27-9AF9-0A3D58DCD5A1 Q34325329-C401A7D3-E82B-4F48-A631-30875DA17E44 Q35192790-42698DDD-9AE7-478A-958F-3B83E8114CBD Q36269852-4A6AC3E1-E8A9-4D5B-B8CB-3B174A6A4E8D Q36979140-015385F6-C45B-4F12-9340-780699E916C8 Q37029370-14C98464-49CF-4BA7-80B2-D2B72904ABA7 Q37273186-FADED4A2-D0CC-4AC4-978E-A13988861343 Q37524930-669292D6-46DC-46AC-A21A-ED1D89CC7A3D Q37590909-8667446C-B763-46F4-AB92-6019D19978F0 Q37697843-09AC7ED1-A28D-4787-9022-536BB5A488A9 Q37725578-94BB0ED2-EDD3-43CF-A89E-368062AEF0EC Q38109511-6CF675C2-C0C0-4D38-A3CC-FC74B72F07BD Q38131563-D32B6A36-E141-4C0A-8882-9DFBF1F83ED6 Q38188591-78685431-2630-445D-8BB4-7EF467611644 Q38191811-3B49D8F5-A465-4F78-B1D1-DF74ED0B4F50 Q38206275-9AC287F1-908C-4053-8BAA-3345AD9313B6 Q38289029-BBE6A0BB-153A-4DF9-9162-196A841E934F Q38317235-C7DF4DF3-5C56-486E-8051-3478523A077F Q38379829-04A42F9F-8692-4E10-8829-973E4880AE8A Q38434473-66FC5A6A-9C0A-49CA-BEF4-7F8A0B5E2764 Q38550992-1A6DCA5F-D4FB-453E-A297-FE49225E6049 Q38632313-A9E80020-FF2F-482C-9F66-2593FA698044 Q38636154-3E7E80E6-7775-44B9-982D-AF272C6D91B3 Q38655388-ADC99DF3-2DF0-43D2-ADF8-49B21A5517E2 Q38707852-8C4E574B-4038-4CA4-B89B-9DF8D0C0AF01 Q38708600-5C1F6D0E-73EA-472B-9D5F-847A400FD79C Q38748185-2F913804-3B9D-4971-B6EE-3E3736E0EE56 Q38896683-0729B6F3-DEA0-4588-98BE-E8622BD49965 Q38917848-9C1C2E86-C0EF-4747-970F-9BB6F0AD402F Q38932868-51DABB54-F11A-47C5-A380-3199702B5F82 Q38984055-17B6A230-A34A-49C8-8B97-796F3A7128CF Q39360775-43B58BE6-5FD0-4B87-9D17-624D51D49B35

P2860

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

Item

http://www.wikidata.org/entity/Q33405150

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu